Ways to reduce cardiovascular disease in diabetes

Diabetes Technology and Therapeutics

Volumn 14, Issue SUPPL. 1, 2012, Pages

  Garg, Satish K ^a,b   Didomenico, Dominic ^a   Switzer, Sean ^a  

^a UNIVERSITY OF COLORADO DENVER   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLICLAZIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCOSE; HEMOGLOBIN A1C; INCRETIN; INDAPAMIDE PLUS PERINDOPRIL; INSULIN; INSULIN GLARGINE; LOW DENSITY LIPOPROTEIN; ORAL ANTIDIABETIC AGENT;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); COMPUTED TOMOGRAPHIC ANGIOGRAPHY; DIABETIC MICROANGIOPATHY; EARLY DIAGNOSIS; EARLY INTERVENTION; EDITORIAL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN DEPENDENT DIABETES MELLITUS; MAGNETIC RESONANCE ANGIOGRAPHY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; PRIORITY JOURNAL; RISK REDUCTION; SIDE EFFECT; UNITED STATES; WEIGHT GAIN;

ANTIHYPERTENSIVE AGENTS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; EARLY DIAGNOSIS; FEMALE; HUMANS; MALE;

EID: 84861871247     PISSN: 15209156     EISSN: 15578593     Source Type: Journal    
DOI: 10.1089/dia.2012.0100     Document Type: Editorial

References (18)

1. International Diabetes Federation: IDF Diabetes Atlas. Fifth edition. www.idf.org/diabetesatlas/5e/the-global-burden (accessed April 2012).
2. American Diabetes Association: Giabetes statistics. www .diabetes.org/diabetes-basics/diabetes-statistics/?loc =DropDownDB-stats (accessed April 2012).
3. Hu FB, Stampfer MJ, Solomon CG, Liu S, Willet WC, Speizer FE, Nathan DM, Manson JE: The impact of diabetes mellitus on mortality from all causes and coronary heart disease in women: 20 years of follow-up. Arch Intern Med 2001;161: 1717-1723.
4. The effect of intensive treatment of diabetes on the development and progression of long-Term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329:977-986.
5. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:854-865. Erratum in Lancet 1998; 352:1558.
6. Home P: Cardiovascular disease and oral agent glucoselowering therapies in the management of type 2 diabetes. Diabetes Technol Ther 2012;14(Suppl 1):S-33-S-42.
7. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ 2000;321:405-412.
8. Ong KL, Cheung BM, Wong LY, Wat NM, Lam KS: Prevalence, treatment and control of diagnosed diabetes in the US National Health and Nutrition Examination Survey 1999-2004. Ann Epidemiol 2008;18:222-229.
9. Hirsch IB, O'Brien KD: How to best manage glycemia and non-glycemia during the time of acute myocardial infarction. Diabetes Technol Ther 2012;14(Suppl 1):S-22-S-32.
10. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group: Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353:2643-2653.
11. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT: Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-2559.
12. Snell-Bergeon JK, Wadwa RP: Hypoglycemia, diabetes, and cardiovascular disease. Diabetes Technol Ther 2012;14(Suppl 1):S-51-S-58.
13. ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, De Galan BE, Joshi R, Travert F: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-2572.
14. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R,Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD: Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129-139.
15. Lemkes BA, Nieuwdorp M, Hoekstra JBL, Holleman F: The glycocalyx and cardiovascular disease in diabetes: Should we judge the endothelium by its cover? Diabetes Technol Ther 2012;14(Suppl 1):S-3-S-10.
16. Pradeepa R, Prabhakaran D, Mohan V: Emerging economies and diabetes and cardiovascular disease. Diabetes Technol Ther 2012;14(Suppl 1):S-59-S-67.
17. Lebovitz HE, Banerji MA: Non-insulin injectable treatments (glucagon-like peptide-1 and its analogs) and cardiovascular disease. Diabetes Technol Ther 2012;14(Suppl 1):S-43-S-50.
18. Truong UT, Maahs DM, Daniels SR: Cardiovascular disease in children and adolescents with diabetes: Where are we, and where are we going? Diabetes Technol Ther 2012;14(Suppl 1):S-11-S-21.